American consumers pay top dollar for medications they assume are pure and unadulturated. But we don't always get what we pay for, according to researchers who are sounding the alarm about the growing presence of counterfeit drugs in the marketplace.

Thirteen years after then-First Lady Hillary Clinton's 1,000-page universal health-care plan met with derision, an increasing number of public policymakers are coming full circle, advocating mandatory enrollment for everyone and coverage regardless of age, income and pre-existing medical problems

Arizona's health information technology (HIT) industry and health-care delivery system are on the brink of radical transformation as Arizona Health-e Connection prepares to publish its proposal offering a "road map" for development and implementation of a statewide, unified HIT network.

Forty-seven percent of registered voters say that health care is an extremely important consideration in their vote for president, according to a June CNN/Opinion Research Corporation Poll.

The tentative contract agreement that assigned a role to the United Auto Workers in managing the healthcare costs of its General Motors members was a turning point in the relationship between business and labor — and a sign of things to come in a global economy.

Supply expense is the second highest operational cost in hospitals, but traditional healthcare benchmarking doesn't pinpoint factors that contribute to supply-expense performance, nor does it enable hospital supply chain professionals to see how they stack up against similar organizations.

A groundbreaking study has finally put a dollar figure on a previously unanswered question: how much do physicians' practices, due to government regulation, pay to ensure their poorest patients get the right prescription drugs?

A controversial regulation creates a "safe harbor" from antitrust laws for certain aspects of the relationship between suppliers and group purchasing organizations (GPOs) in the healthcare industry.

In the third and final presidential debate on October 15, Senators Barack Obama and John McCain spent some time discussing health care — an issue which, in spite of increasingly dominant concerns about the economy — still seems to matter a great deal to American voters.

The future of the pharmaceutical industry lies in its willingness to share scientific information, tailor drugs for individual patient groups and have the courage to walk away from some therapies in order to improve outcomes in other areas, says Eli Lilly and Company chairman of the board Sidney